专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明专利

CA2701705A1 TRIMERIC IL-1RALPHA 未知
公开(公告)号：CA2701705A1
公开(公告)日：2009-04-16
申请号：CA2701705
申请日：2008-10-08
申请人： ANAPHORE INC
发明人： HOLTET THOR LAS , ANDERSEN MIKKEL HOLMEN , NIELAND JOSEPHUS DIRK
IPC分类号： C07K14/47 , C07K14/545
摘要： Interleuekin-1 receptor antagonists (IL-1Ra) including fusion proteins having a trimerizing domain and an IL-1Ra polypeptide sequence. The fusion proteins are part of trimeric complexes that are used in pharmaceutical compositions for treating diseases mediated by IL-1. Effective treatment of inflammatory diseases, such as rheumatoid arthritis and diabetes, are described.

12. 发明专利

AU2008310902A1 Trimeric IL-1Ra 未知
公开(公告)号：AU2008310902A1
公开(公告)日：2009-04-16
申请号：AU2008310902
申请日：2008-10-08
申请人： ANAPHORE INC
发明人： ANDERSEN MIKKEL HOLMEN , HOLTET THOR LAS , NIELAND JOSEPHUS DIRK
IPC分类号： C07K14/47 , C07K14/545

13. 发明申请

WO2012018616A2 POLYPEPTIDES THAT BIND TRAIL-R1 AND TRAIL-R2 审中-公开
标题翻译：包含TRAIL-R1和TRAIL-R2的多聚体
公开(公告)号：WO2012018616A2
公开(公告)日：2012-02-09
申请号：PCT/US2011/045347
申请日：2011-07-26
申请人： ANAPHORE, INC. , BOWDISH, Katherine , KRETZ-ROMMEL, Anke , RENSHAW, Mark , LIN, Bin , DE SILVA CORREIA, Jean , FERRINI, Roger , CHEN, Elise
发明人： BOWDISH, Katherine , KRETZ-ROMMEL, Anke , RENSHAW, Mark , LIN, Bin , DE SILVA CORREIA, Jean , FERRINI, Roger , CHEN, Elise
IPC分类号： A61K38/17
CPC分类号： C07K14/4726 , A61K38/00 , C07K2319/33 , C07K2319/70 , C07K2319/74 , G01N33/6845
摘要： Agonists for TRAIL death receptors including polypeptides that bind to TRAIL death receptor TRAIL-R1 (DR4) and/or TRAIL-R2 (DR5) and optionally having a multimerizing, e.g. trimerizing domain. Agonists are described that do not bind to TRAIL decoy receptors. The multimerizing domain may be derived from human tetranectin. The agonists can induce apoptosis in pathogenic cells expressing a TRAIL death receptor. Pharmaceutical compositions are described for treating diseases associated with cells expressing DR4 and DR5, such as tumor cells. Methods for selecting polypeptides and preparing multimeric complexes.
摘要翻译：用于TRAIL死亡受体的激动剂，包括结合TRAIL死亡受体TRAIL-R1（DR4）和/或TRAIL-R2（DR5）的多肽，并且任选地具有多聚化，例如，三聚域。描述了不结合TRAIL诱饵受体的激动剂。多聚化结构域可以衍生自人类tetranectin。激动剂可诱导表达TRAIL死亡受体的致病细胞凋亡。描述了用于治疗与表达DR4和DR5的细胞例如肿瘤细胞相关的疾病的药物组合物。选择多肽并制备多聚体复合物的方法。

14. 发明申请

WO2009062195A3 FUSION PROTEINS OF MANNOSE BINDING LECTINS FOR TREATMENT OF DISEASE 审中-公开
标题翻译：用于治疗疾病的万能结合胶原蛋白的融合蛋白
公开(公告)号：WO2009062195A3
公开(公告)日：2009-12-03
申请号：PCT/US2008083062
申请日：2008-11-10
申请人： ANAPHORE INC , KYNEB MAJBRITT HAUGE , ANDERSEN MIKKEL HOLMEN , ETZERODT MICHAEL , HOLTET THOR LAS
发明人： KYNEB MAJBRITT HAUGE , ANDERSEN MIKKEL HOLMEN , ETZERODT MICHAEL , HOLTET THOR LAS
IPC分类号： C07K14/47 , C12N15/09
CPC分类号： C07K14/4726 , C07K2319/73 , C07K2319/74
摘要： Fusion proteins having sequences that target specific moieties such as carbohydrates, lipids, and/or proteins that are associated with certain cell types and/or pathogens; and a sequence that induces effector function are provided. The disclosure also provides nucleic acids encoding the fusion proteins, as well as pharmaceutical compositions, methods of use, and methods of treating conditions or diseases such as infectious diseases, cancers, immune related disorders and other ailments, that include the fusions proteins described herein.
摘要翻译：具有靶向与特定细胞类型和/或病原体相关的特定部分如碳水化合物，脂质和/或蛋白质的序列的融合蛋白; 并提供诱导效应子功能的序列。本公开还提供了编码融合蛋白的核酸，以及药物组合物，使用方法，以及治疗诸如感染性疾病，癌症，免疫相关病症和其它疾病的疾病的方法，其包括本文所述的融合蛋白。

15. 发明申请

WO2009062195A2 FUSION PROTEINS OF MANNOSE BINDING LECTINS FOR TREATMENT OF DISEASE 审中-公开
标题翻译：人胰蛋白酶融合蛋白治疗疾病
公开(公告)号：WO2009062195A2
公开(公告)日：2009-05-14
申请号：PCT/US2008/083062
申请日：2008-11-10
申请人： ANAPHORE, INC. , KYNEB, Majbritt, Hauge , ANDERSEN, Mikkel, Holmen , ETZERODT, Michael , HOLTET, Thor, Las
发明人： KYNEB, Majbritt, Hauge , ANDERSEN, Mikkel, Holmen , ETZERODT, Michael , HOLTET, Thor, Las
IPC分类号： C07K14/47 , C12N15/09
CPC分类号： C07K14/4726 , C07K2319/73 , C07K2319/74
摘要： Fusion proteins having sequences that target specific moieties such as carbohydrates, lipids, and/or proteins that are associated with certain cell types and/or pathogens; and a sequence that induces effector function are provided. The disclosure also provides nucleic acids encoding the fusion proteins, as well as pharmaceutical compositions, methods of use, and methods of treating conditions or diseases such as infectious diseases, cancers, immune related disorders and other ailments, that include the fusions proteins described herein.
摘要翻译：具有靶向与特定细胞类型和/或病原体相关的特定部分例如碳水化合物，脂质和/或蛋白质的序列的融合蛋白; 并提供诱导效应子功能的序列。本公开还提供了编码融合蛋白的核酸，以及包括本文所述的融合蛋白的药物组合物，使用方法和治疗病症或疾病例如传染病，癌症，免疫相关病症和其他疾病的方法。

16. 发明申请

US20120021995A1 Polypeptides that Bind TRAIL-R1 and TRAIL-R2 审中-公开
标题翻译：绑定TRAIL-R1和TRAIL-R2的多肽
公开(公告)号：US20120021995A1
公开(公告)日：2012-01-26
申请号：US13190914
申请日：2011-07-26
申请人： Katherine Bowdish , Anke Kretz-Rommel , Mark Renshaw , Bing Lin , Jean de Silva Correia , Roger Ferrini , Elise Chen
发明人： Katherine Bowdish , Anke Kretz-Rommel , Mark Renshaw , Bing Lin , Jean de Silva Correia , Roger Ferrini , Elise Chen
IPC分类号： A61K38/16 , A61P35/00 , A61K38/10 , C07K7/04 , C07K14/00
CPC分类号： C07K14/4726 , A61K38/00 , C07K2319/33 , C07K2319/70 , C07K2319/74 , G01N33/6845
摘要： Agonists for TRAIL death receptors including polypeptides that bind to TRAIL death receptor TRAIL-R1 (DR4) and/or TRAIL-R2 (DR5) and optionally having a multimerizing, e.g. trimerizing domain. Agonists are described that do not bind to TRAIL decoy receptors. The multimerizing domain may be derived from human tetranectin. The agonists can induce apoptosis in pathogenic cells expressing a TRAIL death receptor. Pharmaceutical compositions are described for treating diseases associated with cells expressing DR4 and DR5, such as tumor cells. Methods for selecting polypeptides and preparing multimeric complexes.
摘要翻译：用于TRAIL死亡受体的激动剂，包括结合TRAIL死亡受体TRAIL-R1（DR4）和/或TRAIL-R2（DR5）的多肽，并且任选地具有多聚化，例如，三聚域。描述了不结合TRAIL诱饵受体的激动剂。多聚化结构域可以衍生自人类tetranectin。激动剂可诱导表达TRAIL死亡受体的致病细胞凋亡。描述了用于治疗与表达DR4和DR5的细胞例如肿瘤细胞相关的疾病的药物组合物。选择多肽并制备多聚体复合物的方法。

17. 发明专利

ES2427974T3 Corte de proteínas de fusión mediante la utilización de la proteasa granzima B 未知
公开(公告)号：ES2427974T3
公开(公告)日：2013-11-05
申请号：ES04729047
申请日：2004-04-23
申请人： ANAPHORE INC , HOFFMANN LA ROCHE , HOFFMANN LA ROCHE
发明人： LORENTSEN RIKKE HOEGH , FYNBO CHARLOTTE HARKJAER
IPC分类号： C07K19/00 , C12N9/64
摘要： Método para la preparación de un polipéptido de interés en forma auténtica, comprendiendo dicho métodolas etapas de: (i) proporcionar una proteína de fusión que comprende, de extremo N-terminal a C-terminal, (a) una pareja de fusión,(b) un sitio de reconocimiento de proteasa granzima B que comprende un sitio de corte de proteasa granzima B, enel que el sitio de reconocimiento presenta una secuencia de aminoácidos seleccionada de entre el grupo queconsiste de ICPD ↓, ISAD ↓, ISSD ↓, ITPD ↓, VAPD ↓, VATD ↓, VCTD ↓, VDPD ↓, VDSD ↓, VGPD ↓, VRPD ↓, VTPD ↓,LEED ↓, LEID ↓, LGND ↓, LGPD ↓, AQPD ↓, y en el que: ↓ es el sitio de corte para dicha proteasa granzima B, o en el que el sitio de reconocimiento presenta la fórmulageneral: en la que P4 es el aminoácido I o V P3 es el aminoácido E, Q o M P2 es X, en donde X se refiere a cualquieraminoácido, Pi es el aminoácido D, y ↓ es el sitio de corte para dicha proteasa granzima B, y (c) un polipéptido deinterés, en el que dicho sitio de corte es contiguo al polipéptido de interés, y (ii) poner en contacto dicha proteína de fusión con la proteasa granzima B para cortarla en dicho sitio de corte,rindiendo dicho polipéptido de interés en forma auténtica.

18. 发明专利

AU2010303879A1 Combinatorial libraries based on C-type lectin domain 未知
公开(公告)号：AU2010303879A1
公开(公告)日：2012-05-24
申请号：AU2010303879
申请日：2010-02-10
申请人： ANAPHORE INC
发明人： WILD MARTHA , KRETZ-ROMMEL ANKE , BOWDISH KATHERINE , RENSHAW MARK
IPC分类号： C12N15/10 , C07K14/47
摘要： This invention relates to polypeptide libraries comprising polypeptides having a C-type lectin domain (CTLD) with a randomized loop region, as well as nucleic acid libraries comprising nucleic acid molecules encoding such polypeptides. The invention also relates to methods for generating the randomized polypeptides and the polypeptide libraries. The invention further relates to methods of screening the polypeptide and nucleic acid libraries based on the specific binding of the modified CTLDs to a target molecule of interest. The invention also relates to polypeptides derived from such libraries that bind to target molecules of interest.

19. 发明专利

NZ561162A Human granzyme B protease variant wherein cystein 228 is mutated to phenylalanine 未知
公开(公告)号：NZ561162A
公开(公告)日：2009-11-27
申请号：NZ56116204
申请日：2004-04-23
申请人： HOFFMANN LA ROCHE , ANAPHORE INC
发明人： LORENTSEN RIKKE HOEGH , FYNBO CHARLOTTE HARKJAER
IPC分类号： C07K19/00 , C12N9/64
摘要： Disclosed is a human Granzyme B protease variant wherein the Cystein residue no. 228 (chymotrypsinogen numbering) is mutated to Phenylalanine. (62) Divided Out of 543557

20. 发明专利

AT431851T 未知
公开(公告)号：AT431851T
公开(公告)日：2009-06-15
申请号：AT01270552
申请日：2001-12-13
申请人： ANAPHORE INC
发明人： ETZERODT MICHAEL , HOLTET THOR , GRAVERSEN NIELS , THOGERSEN HANS
IPC分类号： C12N15/09 , C12N15/12 , C07K14/47 , C07K19/00 , C12N15/10 , C12N15/62 , C12P21/02
摘要： A novel family of protein libraries comprising CTLDs (C-type Lectin-Like Domains) in which internal polypeptide loop-regions lining the ligand binding sites in CTLDs have been replaced with ensembles of completely or partially randomised polypeptide segments. Tetranectin CTLDs were chosen as framework for the preferred embodiment of the invention; and versatile phagemid vectors useful in the generation and manipulation of human and murine tetranectin CTLD libraries are disclosed as part of this invention. Tetranectin CTLDs in monomeric as well as in trimeric form are efficiently displayed as gene III fusions in fully functional form by the recombinant fd phage display vector. CTLD derivatives with affinity for new ligands may readily be isolated from libraries of vectors displaying CTLDs, in which loop-regions have been randomised, using one or more rounds of enrichment by screening or selection followed by amplification of the enriched subpopulation in each round. The efficiency with which protein products containing CTLDs with new binding properties can be produced, e.g. by bacterial expression and in vitro refolding, in mono-, tri-, or multimeric formats provides important advantages in terms of simplicity, cost and efficiency of generation, production and diagnostic or therapeutic applications in comparison to recombinant antibody derivatives.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式